Surgery Treatment Improved the Overall Survival Rate in Locoregional Myxoid Leiomyosarcoma than Other Myxosarcomas in the United States

Table 1

Demographic data, tumor characteristics, and treatment modality of locoregional myxoid liposarcoma, locoregional myxoid chondrosarcoma, and locoregional myxoid leiomyosarcoma in the Unites States based on the SEER database.

Demographic chch.	Myxoid liposarcoma; Total (); (%)	Myxoid chondrosarcoma; Total (); (%)	Myxoid leiomyosarcoma; Total (); (%)	value; sig (0.05)
Disease
Age (years)				0.001
<50	687; 49.1%	196; 55.1%	47; 36.4%
>50	711; 50.9%	160; 44.9%	82; 63.6%
Sex				0.0001
Male	831; 59.4%	213; 59.8%	23; 17.8%
Female	567; 40.6%	143; 40.2%	106; 82.2%
Race				0.002
White	1153; 82.5%	273; 76.7%	100; 77.5%
Black	135; 9.7%	52; 14.6%	24; 18.6%
Other	110; 7.9%	31; 8.7%	5; 3.9%
Grade				0.0001
Grade I	390; 27.9%	49; 13.8%	10; 7.8%
Grade II	459; 32.8%	116; 32.6%	21; 16.3%
Grade III	106; 7.6%	35; 9.8%	25; 19.4%
Grade IV	112; 8.0%	18; 5.1%	21; 16.3%
Unknown	331; 23.7%	138; 48.8%	52; 40.3%
Primary site				0.0001
Heart	1279; 91.5%	228; 64.0%	43; 33.3%
Retroperitoneum	68; 4.9%	1; 0.3%	5; 3.9%
Bones and joints	4; 0.3%	115; 32.3%	0; 0.0%
Female genital organs	3; 0.2%	0; 0.0%	74; 57.4%
Digestive system	10; 0.7%	0; 0.0%	4; 3.1%
Others	34; 2.4%	12; 3.4%	3; 2.3%
Surgery				0.0001
Yes	1331; 95.2%	317; 89.0%	118; 91.5%
No	67; 4.8%	39; 11.0%	11; 8.5%
Radiotherapy				0.596
Yes	658; 47.1%	157; 44.1%	59; 45.7%
No	740; 52.9%	119; 55.9%	70; 54.3%
Chemotherapy				0.002
Yes	147; 10.5%	61; 17.1%	18; 14.0%
No	1251; 89.5%	259; 82.9%	111; 86.0%
Cause-specific death to cancer				0.0001
Yes	120; 8.6%	83; 23.3%	36; 27.9%
No	1278; 91.4%	273; 76.7%	93; 72.1%

chch: characteristics.